Given that current standards of care for diseases characterized by aberrant angiogenesis such as neovascular age-related macular degeneration and diabetic retinopathy often lose efficacy over time [59], therapeutic targeting of IRE1α may provide additional benefits. This evidence concerns the gene ERN1 and age-related macular degeneration.